Aryl Hydrocarbon Hydroxylases

• 

  Subject Areas on Research

  • 3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency. 
  • A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. 
  • A pharmacogenetic versus a clinical algorithm for warfarin dosing. 
  • A preliminary analysis of interactions between genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of young adults. 
  • Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? 
  • Analysis of medaka cytochrome P450 3A homotropic and heterotropic cooperativity. 
  • Anthracenedione antineoplastic agent effects on drug metabolism in vitro and in vivo: relationship between structure and mechanism of inhibition. 
  • Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. 
  • Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. 
  • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. 
  • Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. 
  • Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. 
  • CYP1B1 knockdown does not alter synergistic developmental toxicity of polycyclic aromatic hydrocarbons in zebrafish (Danio rerio). 
  • CYP1B1, MYOC, and LTBP2 mutations in primary congenital glaucoma patients in the United States. 
  • CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. 
  • CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. 
  • CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. 
  • Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. 
  • Characterization of the effects of tebufelone on hepatic cytochromes P450 in the beagle dog. 
  • Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Cloning genes that encode drug-metabolizing enzymes: developmental pharmacology and teratology. 
  • Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. 
  • Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. 
  • Cytochrome P450 2C19 polymorphism and clopidogrel after MI. 
  • Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. 
  • DEET (N,N-diethyl-m-toluamide) alone and in combination with permethrin increased urinary excretion of 6beta-hydroxycortisol in rats, a marker of hepatic CYP3A induction. 
  • Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. 
  • Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. 
  • Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. 
  • Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. 
  • Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis. 
  • Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. 
  • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. 
  • Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. 
  • Effect of age and gender on the activity of human hepatic CYP3A. 
  • Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms. 
  • Enantiomeric metabolic interactions and stereoselective human methadone metabolism. 
  • Estimation of the warfarin dose with clinical and pharmacogenetic data. 
  • Estrogen metabolism within the lung and its modulation by tobacco smoke. 
  • Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. 
  • Expression and subcellular distribution of mouse cytochrome P1-450 mRNA as determined by molecular hybridization with cloned P1-450 DNA. 
  • Fibronectin-mediated hepatocyte shape change reprograms cytochrome P450 2C11 gene expression via an integrin-signaled induction of ribonuclease activity. 
  • First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. 
  • Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. 
  • Genetic-based dosing in orthopedic patients beginning warfarin therapy. 
  • Genome-wide association study of smoking behaviours in patients with COPD. 
  • Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. 
  • High-performance liquid chromatographic method for measurement of cytochrome P450-mediated metabolism of 7-ethoxy-4-trifluoromethylcoumarin. 
  • Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. 
  • Human halothane reduction in vitro by cytochrome P450 2A6 and 3A4: identification of low and high KM isoforms. 
  • Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. 
  • Identification and characterization of a cDNA encoding cytochrome P450 3A from the fresh water teleost medaka (Oryzias latipes). 
  • Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. 
  • Identification, characterization, and ontogeny of a second cytochrome P450 3A gene from the fresh water teleost medaka (Oryzias latipes). 
  • In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. 
  • Induction of cytochrome P(1)450 RNA and benzo[a]pyrene metabolism in primary human hepatocyte cultures with benzanthracene. 
  • Induction of pulmonary and hepatic cytochrome P-450 species by coal fly ash inhalation in rats. 
  • Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. 
  • Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. 
  • Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. 
  • Inhibition of coal fly ash polycyclic aromatic hydrocarbons and metals induced mixed-function oxidase activity in rat lung and liver by vitamin A and citrate. 
  • Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. 
  • Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sample of young adults. 
  • Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. 
  • Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. 
  • Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement". 
  • Mechanism of autoinduction of methadone N-demethylation in human hepatocytes. 
  • Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. 
  • Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by human CYP1B1 genetic variants. 
  • Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. 
  • Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. 
  • Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. 
  • Molecular characterization of CYP2B6 substrates. 
  • Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel. 
  • On the occurrence of cytochrome P-450 and aryl hydrocarbon hydroxylase activity in rat brain. 
  • Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). 
  • Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study. 
  • Pharmacogenetic guidance for antiplatelet treatment. 
  • Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. 
  • Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. 
  • Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. 
  • Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. 
  • Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. 
  • Race, ethnicity, ancestry, and pharmacogenetics. 
  • Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. 
  • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. 
  • Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. 
  • Role of CYP2B6 in stereoselective human methadone metabolism. 
  • Role of cytochrome P4502B6 in methadone metabolism and clearance. 
  • Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. 
  • Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. 
  • Screening of 16 common therapeutic drugs. Possible association with the Ah locus. 
  • Screening of CYP1B1 and LTBP2 genes in Saudi families with primary congenital glaucoma: genotype-phenotype correlation. 
  • Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. 
  • Single-dose disulfiram does not inhibit CYP2A6 activity. 
  • Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. 
  • Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. 
  • Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. 
  • Structure-activity relationships of chlorinated benzenes as inducers of hepatic cytochrome P-450 isozymes in the rat. 
  • Suppression of male-specific cytochrome P450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl in rat liver is not causally related to changes in serum testosterone. 
  • Synergistic induction of AHR regulated genes in developmental toxicity from co-exposure to two model PAHs in zebrafish. 
  • Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 
  • The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. 
  • The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. 
  • The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. 
  • The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. 
  • The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. 
  • The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. 
  • The long and winding road to warfarin pharmacogenetic testing. 
  • The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. 
  • The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 
  • Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis. 
  • Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? 
  • Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. 
  • Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. 
  • Use of pharmacogenetics to guide warfarin therapy. 
  • Vitamins E and K induce aryl hydrocarbon hydroxylase activity in human cell cultures. 
  • We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity.